Literature DB >> 6743490

Antihypertensive and renal effects of nicardipine.

B A van Schaik, A E van Nistelrooy, G G Geyskes.   

Abstract

Both the acute blood pressure lowering and renal effects of the calcium antagonist nicardipine and those after 1 week's treatment were investigated in 10 normotensive volunteers and in 10 patients with mild to moderate essential hypertension. After 1 week of placebo, nicardipine was administered orally for 1 week (20 mg three times daily), Investigations, done on the first and last day of nicardipine treatment were compared with those on the last day of placebo. During water loading, nicardipine increased urinary volume and urinary excretion of sodium significantly after 1 week nicardipine treatment. In the normotensive group the natriuretic effect was caused by a decrease of fractional proximal and distal reabsorption of sodium. In the hypertensive group the natriuresis was achieved mainly by an increase of the rate of glomerular filtration (GFR) and also by a slight distal effect. Our results show that nicardipine had natriuretic effects. There were trends suggesting that the renal effects may differ between patients with essential hypertension and normotensive volunteers, but the findings might also be related to differences in age between the groups.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743490      PMCID: PMC1463589          DOI: 10.1111/j.1365-2125.1984.tb05022.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  A non-chromatographic non-extraction radioimmunoassay for serum aldosterone.

Authors:  T Ogihara; K Iinuma; K Nishi; Y Arakawa; A Takagi
Journal:  J Clin Endocrinol Metab       Date:  1977-10       Impact factor: 5.958

Review 2.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

3.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

4.  [Effect of BAY a 1040 on renal function in hypertension].

Authors:  K Klütsch; P Schmidt; J Grosswendt
Journal:  Arzneimittelforschung       Date:  1972-02

5.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

6.  Antihypertensive effect of fractionated sublingual administration of nifedipine in moderate essential hypertension.

Authors:  M Thibonnier; F Bonnet; P Corvol
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

7.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

8.  Antihypertensive effect of (4-2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, Bay-a 1040), a new coronary dilator.

Authors:  M Murakami; E Murakami; N Takekoshi; M Tsuchiya; T Kin
Journal:  Jpn Heart J       Date:  1972-03

9.  [Effects of intravenous nicardipine hydrochloride (YC 93), a calcium antagonist, on renal function (author's transl)].

Authors:  S Yokoyama; T Kaburagi
Journal:  Nihon Jinzo Gakkai Shi       Date:  1981-08

10.  Antihypertensive and hormonal effects of single oral doses of captopril and nifedipine in essential hypertension.

Authors:  M E Soto; M Thibonnier; O Sire; J Menard; P Corvol; P Milliez
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  15 in total

Review 1.  Renal effects of calcium entry blockers.

Authors:  L M Ruilope; J M Alcazar
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  The natriuresis following oral administration of the calcium antagonists--nifedipine and nitrendipine.

Authors:  M D Ene; P J Williamson; C J Roberts; G Waddell
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

3.  Influence of nicardipine on blood pressure, renal function and plasma aldosterone in normotensive volunteers.

Authors:  B A van Schaik; R J Hene; G G Geyskes
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

4.  Calcium channel blockers--are they diuretics?

Authors:  M A Young; R D Watson; T J Stallard; W A Littler
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 5.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

6.  Nitrendipine and the humoral control of sodium homeostasis.

Authors:  D R Forsyth; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

7.  Acute natriuretic effect of nifedipine in hypertensive patients and normotensive controls--a proximal tubular effect?

Authors:  L R Krusell; C K Christensen; O Lederballe Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Treatment of intraoperative hypertension with enflurane, nicardipine, or human atrial natriuretic peptide: haemodynamic and renal effects.

Authors:  F Goto; S Kato; I Sudo
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

9.  The acute renal haemodynamic and endocrine response to felodipine in normal man.

Authors:  D A Jenkins; K Craig; A D Cumming; M L Watson
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 10.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.